Compare BFS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | HROW |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 1.1B |
| IPO Year | 1996 | 2008 |
| Metric | BFS | HROW |
|---|---|---|
| Price | $28.57 | $26.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $43.00 | ★ $63.00 |
| AVG Volume (30 Days) | 121.8K | ★ 582.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $289,843,000.00 | N/A |
| Revenue This Year | $7.44 | $28.41 |
| Revenue Next Year | $3.40 | $58.14 |
| P/E Ratio | $58.20 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $28.56 | $26.96 |
| 52 Week High | $38.42 | $54.98 |
| Indicator | BFS | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 34.95 |
| Support Level | $28.56 | N/A |
| Resistance Level | $35.04 | $30.28 |
| Average True Range (ATR) | 0.65 | 1.29 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 22.93 | 18.92 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.